SOFINNOVA PARTNERS - Key Persons
Job Titles:
- Investor Relations and Reporting Officer
Job Titles:
- Analyst, Sofinnova Partners - Digital Medicine Strategy
Aishu is an Analyst with the Sofinnova Digital Medicine Strategy. She joined us in 2023 after taking on a full-time role as an Investment Fellow at BioGeneration Ventures.
Her ten-year academic career weaved together neuroscience, engineering, and computation across Asia, Europe, and the U.S. Aishu says her transition into venture capital was "sparked by a genuine eagerness to learn about and support advancements at the confluence of scientific exploration and computation."
Job Titles:
- Partner, Sofinnova Partners - Biovelocita Strategy
Alex is a Partner in the Sofinnova Biovelocita Strategy. He is an experienced biopharma company builder and a serial CEO, most recently serving as the founding CEO of Alchemab Therapeutics, which raised an $82m Series A investment round.
He was CEO of the clinical stage dermatology company Creabilis Therapeutics until its acquisition by Sienna Biopharmaceuticals Inc. in 2016.
"Sofinnova's Biovelocita Strategy is a perfect fit for me," Alex said. "Together, we expect to build an exciting portfolio of leading biotechnology companies from cutting-edge European science."
Alex's other company-building roles include serving as CEO of Camphos and Zarodex, Entrepreneur in Residence at Bicycle Tx, and as a Venture Partner with SV Health Investors in London. He is currently Chair of the Board at two start-ups, Ensocell and Sevenless.
He previously held a range of senior project management positions within Pfizer's R&D organization, including working as part of a small team leading the restructuring of Pfizer's drug development capabilities.
Early in his career, Alex gained valuable management and commercial experience at Ford Motor Company and the Visteon Corporation. He holds a BEng in Mechanical Engineering from the University of Sussex and an MBA from Henley Management College, UK.
Andrew joined us in 2023, bringing with him a wealth of experience in the medical devices sector, with expertise in device development, clinical and regulatory strategy, fund-raising, strategic business development, and team leadership.
As a Venture Partner, Andrew investigates global medical device investment opportunities across the Sofinnova Partners platform of strategies. He is currently on the board of May Health and SafeHeal, two companies in the portfolio of Sofinnova's medtech incubator strategy, MD Start.
"I share Sofinnova's passion for finding, nurturing and bringing new medical device therapies to patients," Weiss said when he was appointed Venture Partner." Having worked both informally and as a portfolio company CEO with Sofinnova for the past 20 years, I know that they have the best team, and are the gold-standard medical device venture group."
In 2013, Andrew was brought in as CEO to lead ReCor Medical, a company founded in 2009 by Mano Iyer, then an entrepreneur in residence at Sofinnova and now a partner in the Sofinnova medtech acceleration team. Mr. Weiss led ReCor, a pioneer in the use of ultrasound renal denervation to treat hypertension, as it scaled up to 175 employees, went through its clinical trials and was purchased by Otsuka Medical Devices in 2018. Sofinnova Partners was the sole VC investor in ReCor at the time of the sale. Andrew stayed at the combined company until 2023, the year ReCor received FDA approval for its Renal Denervation System.
Before he took the reins at ReCor, Andrew held leadership roles including President & CEO of Vital Images (acquired by Toshiba), VP & General Manager of the Medtronic Surgical Navigation Systems and Neurological businesses, and President & CEO of CoAxia, which was sold to Zoll Medical.
Andrew has also been an advisor to and board member of a number of medical device companies in the US, Europe and Israel.
He is a graduate of the Massachusetts Institute of Technology with a degree in mechanical and electrical engineering and has an MBA from the Columbia University Graduate School of Business
Job Titles:
- Associate
- Associate, Sofinnova Partners - Capital Strategy
Job Titles:
- Venture Partner
- Associate With the Sofinnova Industrial Biotech
- Associate, Sofinnova Partners - Industrial Biotech Strategy
Anna is an Associate with the Sofinnova Industrial Biotech strategy. She joined us in 2020.
Previously she worked as an analyst in the innovation department of the EFKO Group, one of the top three Russian food industry groups, where she covered the FoodTech and AgriTech sectors. Prior to that, she was an analyst in the Seeds Department at Bayer Crop Science CIS.
Initially graduating as a marine biologist specializing in luminous invertebrates, Anna has always valued diversity and sustainability. Her tenacity and curiosity were encouraged by a saying from her professors: "The worm is so long, and life is so short," which Anna finds applicable to any project. "Great ideas fade away if we don't support them," she said. "So, finding equilibrium by applying the necessary amount of time to the necessary technologies gives beautiful results."
She holds a BSc in Biology from Moscow State University, and an M.Sc. in Biomedical Science from Skolkovo Institute of Science and Technology.
Job Titles:
- Partner, Sofinnova Partners - MD Start Strategy
Anne has been running our in-house MedTech accelerator, MD Start, since she came on board as a partner in 2015.
She embodies the MD Start team's hands-on approach: Anne is the founding and current CEO of Moon Surgical. She is a Board member of both SafeHeal and May Health - two companies where she was also founding CEO.
"What I like about this job is that it is about building products and companies," Osdoit says. "It is very diverse. It is in different therapeutic areas, in different spaces with different technologies."
Prior to joining Sofinnova, Anne held several key positions at Mauna Kea Technologies, a Paris-based medical technology company with global presence, developing a disruptive "optical biopsy" technology. She was closely involved in multiple financing rounds, including the company's initial public offering on the Paris Euronext, a highly successful operation and the largest public listing for the sector that year.
Job Titles:
- Head of Operations and Projects Office
Anne-Sophie joined Sofinnova Partners in 2023. As Head of Operations and Project Office, she manages the Sofinnova projects portfolio and ensures coordination between Sofinnova platforms.
She has 25 years of experience in the finance industry, in Mergers & Acquisitions, Business Development and Chief Operating Officer positions.
Before joining Sofinnova, Anne-Sophie was Chief Operating Officer at Exane.
Anne-Sophie holds a Master's in Finance from HEC Paris.
Job Titles:
- Principal, Sofinnova Partners - Capital Strategy
Job Titles:
- Chairman
- Managing Partner
- Venture Partner
Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997.
"Life Sciences investing is not just about recognizing good science," Papiernik says, "it's about people - learning how to interact with co-investors, limited partners, and entrepreneurs. Listening, discerning, negotiating, and finding common interests."
When you find the right people to invest in, he adds, "you can bank on them more often than you can predict how the science is going to turn out." He looks for entrepreneurs with the nimbleness to adapt, "even if that means making a major shift from where one starts out on the journey."
Antoine actively invests for our Capital Funds. He has been an initial investor and active board member in a number of public companies, including Actelion, ProQR, Shockwave Medical, NovusPharma (sold to CTI), and Movetis (sold to Shire). Trade sale success stories include CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis), Ethical Oncology Science (EOS, sold to Clovis Oncology) and Recor Medical (sold to Otsuka).
He has also invested in and is a board member of private companies Reflexion Medical, Tissium, Pi-Cardia, SafeHeal, Noema Therapeutics, May Health, Highlife and Inspirna (formerly Rgenix).
Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. He has been selected twice for the Forbes Midas List, an annual ranking recognizing the world's top venture capital investors. Antoine is one of the few European and life science investors to have appeared on the prestigious list.
Job Titles:
- Physician
- Venture Partner
- Associate, Sofinnova Partners - Capital Strategy
Aseem joined us in 2023 as an associate in the Capital team.
Before joining Sofinnova Partners, Aseem was at Achilles Therapeutics, where he was part of the corporate team that supported the company's NASDAQ IPO.
Prior to that, he worked as a consultant at Bain & Company, where he specialized in due diligence for private equity firms acquiring healthcare and life sciences assets.
Aseem is a physician and worked clinically during his Academic Foundation Programme training at Oxford University Hospital Trust in the UK. Then he completed an innovation fellowship at a central London teaching hospital, where he focused on using novel technologies to streamline patient care and improve surgical outcomes.
Aseem holds an MBBS from Imperial College London, and a BA degree in Neuroscience from the University of Cambridge.
Ashvin Rajee joined us in January 2021 as a paralegal officer.
Prior to joining Sofinnova Partners, he worked as a Paralegal for law firms such as Herbert Smith Freehills LLP and companies such as JCDecaux.
After his Master in Business and Tax Law from University of Paris VIII, Ashvin graduated from ENADEP (École nationale de droit et de procédure).
Job Titles:
- Management Company Accounting
Job Titles:
- Head of Communications
- Member of Invest Europe 's Communication Advisory Group
Bommy was previously Director of Communications at Cellnovo Group, an innovative medical technology company specializing in diabetes management, where she led the strategic direction and implementation of all communications and digital marketing activities. Prior to that, she was Director of Digital Marketing at Mauna Kea Technologies, a publicly-listed medical device company focused on confocal endomicroscopy. Bommy began her career as Senior Editor and Producer at the International Herald Tribune and was part of a pioneering team that brought digital journalism to the newspaper.
Bommy is an active member of Invest Europe's Communication Advisory Group, which focuses on reputation management and communication-related issues affecting European private equity and venture capital.
Job Titles:
- Administrative and Financial Manager
Job Titles:
- Partner, Sofinnova Partners - Crossover Strategy
Cedric joined us in June 2018, bringing his 18 years of experience in life sciences investment banking. He is a partner on the Crossover team.
Cedric joined from Oddo BHF where he was managing director and head of healthcare in the corporate finance department. In 2017, Oddo BHF was the top ranked firm for European biotech equity capital market deals.
Prior to this, he was director at Bryan Garnier & Co where he completed several sizable cross-border transactions, including Galapagos, DBV, Ablynx, and Celyad. In total, he has managed more than 2 billion euros in European healthcare transactions.
Cedric brings to the Crossover team his transactional expertise in the biopharma industry, as well as an extensive network of key opinion leaders, bankers and lawyers.
Cedric was well known to the Sofinnova team before he came onboard, having executed several mandates for portfolio companies.
He said the Sofinnova Crossover team was taking a different approach compared with crossover transactions in the U.S., which typically involve investing just ahead of a company's IPO.
"We are more like late-stage VC investors," he said. "It's really the stage of maturity of the company that is important for us. Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage development and proof of concept," then help them get ready for what comes next - usually a listing on the Nasdaq, and/or a deal with a major pharma or healthcare company.
Before his corporate finance career, Cedric spent 10 years as a healthcare equity analyst, and was several times EXTEL top ranked (awarded for both individual and team performances) at Natixis and Fortis. He was in charge of coverage of listed biotech and pharma companies.
Cedric holds a Master's in Economics and post-graduate diploma in Finance and Taxation (Sorbonne) and diploma from the Société Française des Analystes Financiers (SFAF).
Christophe joined Sofinnova Partners in 2016 and handles all administrative and financial issues related to the funds and the management company.
He has 16 years of experience in the private investment industry, handling administration and financing of management companies.
Before joining Sofinnova, Christophe was chief financial officer and conducting officer at PO Participations S.A., where he was involved in the debt activity and in the oversight of delegated activities.
Prior to PO Participations, Christophe worked as chief financial officer in French and Luxembourg management companies. He also worked as a senior audit manager in PricewaterhouseCoopers with a focus on private equity and professionals in the financial sector.
Christophe is Réviseur d'Entreprises in Luxembourg and graduated from the Institut Supérieur du Commerce, a French business school.
Job Titles:
- Venture Partner
- Senior Associate, Sofinnova Partners - Crossover Strategy
Claire joined us in February 2021 as an analyst with the Crossover team. Prior to joining Sofinnova Partners, Claire was an analyst on the Life Sciences team at Andera Partners, where she identified and invested in biotech and medtech companies.
Claire has a PhD in Hemato-Oncology from Paris Diderot University, which she carried out at the Institut Curie, working on elucidating signaling pathways involved in the activity of leukemic-initiating cells in T cell acute lymphoblastic leukemia (T-ALL).
She also holds an MSc from the French engineering school Agrocampus Ouest and a degree in Biopharmaceutical Management from ESCP Business School. Her research has been published in journals such as Nature Communications and Cancer Cell.
Job Titles:
- Associate and Program Manager With the Sofinnova Biovelocita Strategy
- Associate, Program Manager, Sofinnova Partners - Biovelocita Strategy
Cristina is an Associate and Program Manager with the Sofinnova Biovelocita Strategy. She has a strong scientific background and is experienced in early-stage biopharma.
Cristina joined the extended Sofinnova family in 2016, scouting and developing strategic projects with BiovelocITA, the Milan-based accelerator that was co-founded by Sofinnova Partners and inspired the pan-European Biovelocita Strategy.
Previously, Cristina worked in the publishing industry in London, editing a leading journal in cell biology, and in Milan covering editorial and managerial roles with increasing responsibility for Elsevier Italia.
Prior to that, Cristina was a researcher at the CRUK-Wellcome Gurdon Institute in Cambridge and a lecturer for University of Cambridge. She holds a degree in Biological Sciences from the University of Trieste and a PhD in Molecular Genetics from the International School for Advanced Studies (ISAS)/International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste.
"I am very pleased to be part of this team, helping shape the innovation pipeline," she said. "Throughout my career I've worked very closely with scientists on challenging projects, and I am ready to share my experience with new biotech companies."
"I am very pleased to be part of this team, helping shape the innovation pipeline."
Job Titles:
- Venture Partner
- Partner, Sofinnova Partners - MD Start Strategy
Cécile is a Partner in the Sofinnova MD Start Strategy. She joined the firm in 2019, and is currently CEO of BrightHeart, a Sofinnova MD Start III portfolio company. She also brings her operational and strategic expertise to Endoron, another Sofinnova portfolio company, to accelerate the development of the company's highly disruptive technology.
Prior to that, she was CEO of HEPTA Medical, COO of Gradient Denervation Technologies, and director of clinical, regulatory and market access at SafeHeal, the first company created by MD Start II, where she managed the execution of the first-in-human study and regulatory approvals in the EU and US.
Navigating the regulatory landscape is one of Cécile's many talents.
"We need to make sure we start with the right strategy from the get-go because the regulatory strategy is one of the key drivers of the entire project," she says. "It will drive the clinical strategy, but also the R&D strategy. This is really a key entry point for the project."
Prior to joining MD Start, Cécile held various clinical, marketing and regulatory positions in both mature and start-up medical device organizations in the fields of endoscopy, pulmonology, dermatology, surgery and diabetes care; for single and multi-use disposable products and capital equipment.
Cécile holds a bachelor's degree in biomedical engineering from UTC (Université de Technologies de Compiègne) in France, Dalarna University (Sweden) and Favoloro University (Buenos Aires) in Argentina. She also has a degree in corporate finance from HEC in Paris.
Job Titles:
- Associate, Sofinnova Partners - Capital Strategy
Daniel joined us in 2023 as an associate with the Capital Strategy. Prior to joining Sofinnova Partners, Daniel was principal at Plexus Ventures, a US-based global business development consultancy focused on leading healthcare transactions ranging from early biotechs to big pharma. During his tenure, he created and led a team focused on partnering assets in heavily scientific and innovative areas, such as gene and cell therapy, and precision oncology.
Prior to working in the industry, Daniel was an academic researcher. Most recently he was appointed as a Human Frontier Research Fellow at Harvard Medical School and Brigham and Women's Hospital. There, he led research projects on evolutionary developmental biology, as well as translational work on musculoskeletal disease. This work was also supported by the French organization AFM-Téléthon.
Daniel holds a BSc (Honours) in genetics and zoology from Monash University and a PhD in genetics from the Australian Regenerative Medicine Institute in Melbourne, Australia. His original research has been published in journals such as eLife, Nature Communications, PNAS and Development, among others.
Job Titles:
- Reception and Administration
Job Titles:
- Partner, Sofinnova Partners - Digital Medicine Strategy
Edward joined Sofinnova Partners in 2021. He came from M Ventures, Merck KGaA's corporate VC arm, where he focused on investments in cutting-edge digital medicine companies, including developers of the first FDA-approved videogame therapy.
Before that, Edward was in the Life Sciences securities team at Kempen & Co, a pan-European merchant bank, covering listed small- and mid-cap life sciences equities. He started his career as an analyst within the biopharma investment team of M Ventures.
Edward is positive, energetic and purpose-driven - and he enjoys a challenge. In 2012, for instance, he took on the Gobi Desert in an underpowered 1.2L Chevrolet Aveo, which he and his team drove from London to Mongolia to raise money for SOS Children's Villages.
He holds an M.Sc. in Biopharmaceutical Sciences from Leiden University, The Netherlands, with a specialization in pharmacology.
Enzo Petrelluzzi joined Sofinnova Partners in 2023 to help lead a broad effort to upgrade existing information technology tools and implement new ones.
He came to Sofinnova Partners from MAK-SYSTEM, where he was a Project Manager for HealthCare software. He worked for three years on projects like overseeing the implementation of Blood Establishment Computer Software (BECS). Leading projects for clients including Hospitals and Government Ministries, Enzo would coordinate teams of experts, clinicians and developersin order to define and address the needs of software users.
Prior to that, he worked as an Analyst and Assistant Investment Manager with Natixis Assurances, and as a Valuation Analyst for Cushman & Wakefield.
Enzo enjoys reviewing and challenging companies' existing processes and then pairing tools and methods so that teams can be more efficient. He also is into organizing sporting and cultural experiences.
Enzo has a Civil Engineering degree from ESTP Paris, a Master of Research in Civil Engineering of Complex & Nuclear Structures from ESTP Paris, and a Grande Ecole - Master in Management degree from ESSEC Business School.
Estelle is a compliance officer at Sofinnova Partners. She joined us in 2021.
A fourth-generation German graphic designer, Gabriel was raised in a Franco-German environment that helped him gain a nuanced understanding of communication and design on an international scale.
Gabriel started his career as a freelance designer for a publishing company, then secured a position as an art director at MSL group Germany.
At MSL, he was overseeing the conception and production of campaigns for more than 25 clients across various sectors, including healthcare, food, politics, banking, tech, tobacco, spirits, and more.
After several years in Germany, Gabriel returned to France, set on combining the best of both German rigor and French flair - which is what he has been doing since he came to Sofinnova in 2021.
Job Titles:
- Managing Partner
- Venture Partner
Graziano Seghezzi, managing partner, joined us in 2006 and is an active member of the investment team for the Sofinnova Capital Funds.
Graziano serves on the Board of Directors of several companies he helped create and finance, including GlycoEra, Enthera, HotSpot Therapeutics, Erydel, Inotrem, Mission Therapeutics, and Crescendo Biologics. He is responsible for a number of substantial exits, including Corvidia Therapeutics, which was sold to Novo Nordisk for 2.1 billion in 2020; Hookipa Pharma, floated on the Nasdaq in 2019; GlycoVaxyn, sold to GlaxoSmithKline in 2015, and Omthera Pharmaceuticals, which went public on the Nasdaq in 2013 and was then sold to AstraZeneca the same year.
He has also been the main driver behind Sofinnova Partners' growing presence in his native Italy, establishing the country's first biotech accelerator, BiovelocITA, in 2015, and the Sofinnova Telethon Fund in 2018. "For the first time in Italy you had a place where the key ingredients of biotech were working together: dedicated capital, dedicated management, dedicated strategy, and top-tier scientists," Graziano says of the creation of BiovelocITA.
He started his career in venture capital in 2001 at Sofinnova Partners and was at Index Ventures from 2003 to 2006. Prior to that, Graziano spent five years working in academic research at New York University's School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia, Italy, and an MBA from RSM-Erasmus University, The Netherlands.
Job Titles:
- Principal
- Venture Partner
- Principal, Sofinnova Partners - Industrial Biotech Strategy
Guillaume is a principal at Sofinnova Partners. He joined us in 2017 to support our investments in the industrial biotechnology and renewable chemistry sectors.
He started his career in the chemical industry, spending several years in Brussels at Solvay, to develop disruptive technologies for sustainable energies and advanced materials through partnerships between start-ups, research institutes and in-house R&D teams. Then, he joined Solvay Ventures as Investment Manager to work even more closely with entrepreneurs.
Guillaume believes the Sofinnova Partners Industrial Biotech team's scientific expertise is a big factor in its success. "When someone has some synthetic biology technology, and they want to create a company, not many VC investors are able to go deep with them," he said, adding that people who know the sector would say: "if you want to find a deeptech investor, able to make some strong impact and help you make progress in industrial biotech - Sofinnova is it."
Guillaume holds Master's Degrees in Genetics-Immunology (Université Paris Descartes) and in Industrial Biotechnology (Université de Technologie de Compiègne/AgroParisTech). He also holds degrees in Innovation Management (UTC/NEOMA business school) completed by an executive education at Louvain School of Management (Belgium).
Job Titles:
- Venture Partner, Sofinnova Partners - MD Start Strategy
Gérard is a serial entrepreneur in the Medical Devices field.
In the 1980s, he founded Technomed International, a company developing noninvasive therapeutic technologies dedicated to urology. He grew the company to its IPO with 50 million euros in sales and significant profitability.
In the 90s, he founded 2 companies: IMMI, which developed image-guided robotic systems for neurosurgery, and SOMETEC, a maker of noninvasive hemodynamic monitoring systems for anesthesiology and intensive care. Both companies were acquired by U.S.-based companies, ISS and ARROW International respectively.
From 2008 to 2010 he turned around Spine Vision, a developer and manufacturer of spinal implants, as its CEO.
In 2009 Gerard cofounded MD Start, a European incubator for innovative MedTech companies, which created 8 companies. The idea was, he said, "to bridge this gap from the idea of the inventor to possible financing by VCs."
Before becoming an entrepreneur, Gérard began his career with Thomson Group, where he held various management positions in the MedTech branch for over 15 years.
Gérard is an engineer from E.C.E. Paris. He is Executive Chairman of MD Start II, Chairman of CorWave, Chairman of Moon Surgical, Chairman of HEPTA Medical and sits on the Board of Directors of LimFlow, Pixium Vision and Altamir.
Job Titles:
- Managing Partner
- Venture Partner
- Managing Partners and an Active Member
Henrijette Richter is one of our managing partners and an active member of the Capital Strategy team, our flagship fund dedicated to early-stage biotechs and medtechs.
She joined Sofinnova in 2014, and her investments and board involvements include Mozart Therapeutics, Muna Therapeutics, Nitrase Therapeutics, NodThera, Twentyeight-Seven Therapeutics, Asceneuron, Delinia (sold to Celgene), and iOmx Therapeutics.
Henrijette was attracted by Sofinnova Partners' focus on a positive, consensus-oriented environment and its philosophy of investing in people. "Everyone needs to agree. An individual's success is everyone's success," she says. "And when there's a failure, it's everyone's failure - that fosters different conversations when you consider potential investments."
Prior to Sofinnova, Henrijette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris).
Henrijette holds a combined PhD and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.
Hortense Fouilland joined Sofinnova Partners as a legal counsel in 2023. Prior to joining Sofinnova, she was a venture capital / private equity lawyer at Jones Day in Paris and London.
A former member of the Paris bar, Hortense graduated with a Master's degree in Business Law from Paris X University and an L.L.B from the University of Essex. She also has a Master's degree in Management (Grande Ecole) from ESSEC Business School.
Héloise is the Senior HR Officer at Sofinnova Partners. She joined us in 2022, after having served in a similar role at Eurazeo.
She has a Master's in Management from IFAG Lyon, and completed the HR Manager program at SUP des RH in Paris.
Job Titles:
- Partner, Sofinnova Partners - Crossover Strategy
Jacques joined us in 2017 and brings the Crossover team his extensive experience in biopharmaceutical company operations, as well as his know-how when it comes to making private and public investments.
His experience in building a team of international investors to deploy a new strategy is also important for the Crossover team. He is expected to take positions on the board of some of the public companies in which the Fund will invest.
Jacques co-founded in 2008 and managed Ares Life Sciences, a privately owned investment fund with the objective to build and manage a portfolio of companies in life sciences. Jacques built a new team of 9 professionals and invested 1.25 billion in six public and private companies including Euromedic International BV, Esaote Spa, Bronchus Technologies Inc, Santhera Pharmaceuticals, Stallergenes SA, Greer Inc. In June 2015, Stallergenes and Greer merged creating the worldwide market leader in Allergy Immunotherapy.
Jacques had previously spent almost 20 years in the Serono pharmaceutical group, where he was deputy CEO and senior executive vice president for strategic corporate development, responsible for Serono's global strategy and in-licensing initiatives. Jacques also served as Serono's president of European and international sales & marketing and CFO. In his various roles at Serono, Jacques was responsible for several major equity financings of the company, including the $2 billion listing on the NYSE in 2000, one of the largest-ever biotech secondary offerings worldwide. Jacques was also involved in the process that led to the sale of the company to Merck KGA for 14 billion Swiss Francs.
Job Titles:
- Principal, Sofinnova Partners - Digital Medicine Strategy
Job Titles:
- Venture Partner
- Partner, Sofinnova Partners - Crossover Strategy
Job Titles:
- Venture Partner
- Partner, Sofinnova Partners - Industrial Biotech Strategy
Job Titles:
- Partner, Sofinnova Partners - Crossover Strategy
Job Titles:
- Executive Assistant
- Office Manager
Job Titles:
- Venture Partner
- Partner, Sofinnova Partners - Telethon Strategy
Job Titles:
- Venture Partner
- Partner, Sofinnova Partners - Capital Strategy
Job Titles:
- Partner, Sofinnova Partners - MD Start Strategy
Job Titles:
- Partner
- Venture Partner
- Partner, Sofinnova Partners - Biovelocita Strategy
Maria Gabriella Camboni is a Partner with Sofinnova Partners. She was co-founder and CEO of BiovelocITA, Italy's first accelerator dedicated to biotech, and the model for the Sofinnova Biovelocita Strategy.
As a Partner in the Sofinnova Biovelocita Strategy, Gabriella's mission is to work with universities, research organizations and investors to create companies from the most groundbreaking scientific ideas.
"Working with researchers to create new startups is personally very rewarding," she said, "because you're helping to move promising science into the real world, where patients benefit."
Earlier in her career, Gabriella was chief operations officer of Ethical Oncology Science (EOS), a Sofinnova-backed startup devoted to translational research in oncology, which she co-founded with Silvano Spinelli in 2006. EOS was sold to Clovis in 2013.
Job Titles:
- Venture Partner
- Associate, Sofinnova Partners - Industrial Biotech Strategy
Job Titles:
- Venture Partner
- Associate, Program Manager, Sofinnova Partners - Biovelocita Strategy
Job Titles:
- Venture Partner
- Associate, Program Manager, Sofinnova Partners - MD Start Strategy
Job Titles:
- Partner, Sofinnova Partners - Industrial Biotech Strategy
Job Titles:
- Chief Operating Officer
- Partner
Job Titles:
- Venture Partner
- Partner, Sofinnova Partners - Biovelocita Strategy
Job Titles:
- Partner, Sofinnova Partners - Industrial Biotech Strategy
Job Titles:
- Investor Relations and Reporting Manager
Job Titles:
- Events and Community Manager
Job Titles:
- Head of Operations, Italy
Job Titles:
- Partner, Sofinnova Partners - Telethon Strategy
Job Titles:
- Partner, Head of Investor Relations, ESG and Impact
Job Titles:
- Partner, Sofinnova Partners - Digital Medicine Strategy
Job Titles:
- Head of Information Systems
Job Titles:
- Principal, Sofinnova Partners - Telethon Strategy
Job Titles:
- Partner, Sofinnova Partners - Biovelocita Strategy